Skip to main content

Nasdaq Moves to Delist Response Genetics

NEW YORK (GenomeWeb) – Response Genetics may be delisted from the Nasdaq Capital Market after failing to comply with two requirements to remain listed, the firm disclosed in a document filed with the US Securities and Exchange Commission on Dec. 24.

The Los Angeles-based molecular diagnostics firm said in a Form 8-K that it received a delisting determination letter from Nasdaq on Dec. 19 because it was not in compliance with the minimum bid price of $1.00 requirement for continued listing. The letter also stated that the firm was not eligible for an extension to regain compliance because it did not meet the minimum $2.5 million in stockholders’ equity needed for continued listing.

The firm said it intended to appeal the delisting determination by the Dec. 26 deadline, which would stay a suspension of its securities until a hearing process is completed.

On Dec. 11, Nasdaq sent Response Genetics a letter stating that it did not meet a listing requirement calling for a minimum of $2.5 million stockholders' equity. 

The firm said it expects its common stock to be traded on the Over-the-Counter Bulletin Board if it ceases to be listed on the Nasdaq Capital Market.

The Scan

Rise of B.1.617.2 in the UK

According to the Guardian, UK officials expect the B.1.617.2 variant to soon be the dominant version of SARS-CoV-2 there.

Anne Schuchat to Retire

Anne Schuchat is retiring after more than 30 years at the US Centers for Disease Control and Prevention, Politico reports.

US to Share More Vaccines

CNN reports that the US will share 20 million doses of the Moderna, Pfizer, and Johnson & Johnson SARS-CoV-2 vaccines with other countries.

PNAS Papers on Gene Therapy Platform, Aspergillus Metabolome, Undernutrition Model Microbiome

In PNAS this week: approach to deliver protein-based treatments to cells, pan-secondary metabolome of Aspergillus, and more.